Filing Details

Accession Number:
0001209191-23-043306
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-07-25 16:25:05
Reporting Period:
2023-07-21
Accepted Time:
2023-07-25 16:25:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1660334 Verrica Pharmaceuticals Inc. VRCA Pharmaceutical Preparations (2834) 463137900
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1805359 G. Christopher Hayes C/O Verrica Pharmaceuticals Inc.
44 West Gay Street, Suite 400
West Chester PA 19380
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-07-21 100,000 $0.00 115,714 No 4 A Direct
Common Stock Disposition 2023-07-24 33,789 $4.83 81,925 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shallvest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.
  2. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.